Recruiting
Central nervous system lymphoma
RecruitingStudy of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma
Registered drugNo placebo
Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma
Registered drugNo placebo
- Disease:Central nervous system lymphoma
- Substances:RituximabTemozolomide+1
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Rituximab



